Compare Huntington Bancshares Incorporated (HBAN) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Pfizer Inc — how do they compare? Huntington Bancshares Incorporated trades at $15.32 (market cap $31.04B), while Pfizer Inc trades at $28.28 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 5.1× Huntington Bancshares Incorporated's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and Pfizer Inc for 158 Days on average.
| HBAN | PFE | |
|---|---|---|
Market Cap | $31.04B | $158.56B |
Volume | 23,864,172 | 44,138,282 |
Sector | Financials | Health |
52-Week High | $19.27 | $29.02 |
52-Week Low | $15.02 | $23.67 |
Typical Hold Time | 52 Days | 158 Days |
Enterprise Value | $49.57B | $210.06B |
Dividend Yield | 4.04% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.37, up 1.32% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026, with Q3 2026 results pending. Revenue grew to $8.13B in 2025, and the stock trades at a P/E of 11.82, below the industry average. Recent news highlights increased call option activity and a dividend declaration of $0.16 payable in October 2026.
HBAN offers value with a low P/E and strong net income margin of 24.77%, but faces headwinds from interest rate pressures and reduced 2027 earnings guidance. Analyst consensus is a Buy with a $19.60 price target, implying 27% upside, though technical indicators and recent institutional put buying suggest near-term caution. Key risks include margin compression and competitive lending pressures.
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
